The estimated Net Worth of Theresa Wingrove is at least $4.81 Million dollars as of 2 February 2024. Dr Wingrove owns over 29,640 units of Immunogen stock worth over $1,032,982 and over the last 13 years he sold IMGN stock worth over $3,230,837. In addition, he makes $548,205 as Sr. VP of Regulatory Affairs & Quality at Immunogen.
Dr has made over 12 trades of the Immunogen stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 29,640 units of IMGN stock worth $925,954 on 2 February 2024.
The largest trade he's ever made was selling 192,013 units of Immunogen stock on 15 September 2023 worth over $2,964,681. On average, Dr trades about 31,140 units every 102 days since 2011. As of 2 February 2024 he still owns at least 33,066 units of Immunogen stock.
You can see the complete history of Dr Wingrove stock trades at the bottom of the page.
Dr. Theresa G. Wingrove is the Sr. VP of Regulatory Affairs & Quality at Immunogen.
As the Sr. VP of Regulatory Affairs & Quality of Immunogen, the total compensation of Dr Wingrove at Immunogen is $548,205. There are 5 executives at Immunogen getting paid more, with Mark Enyedy having the highest compensation of $3,917,560.
Dr Wingrove is 63, he's been the Sr. VP of Regulatory Affairs & Quality of Immunogen since . There are 4 older and 12 younger executives at Immunogen. The oldest executive at Immunogen, Inc. is Richard Wallace, 68, who is the Independent Director.
Theresa's mailing address filed with the SEC is C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM, MA, 02451.
Over the last 21 years, insiders at Immunogen have traded over $72,947,831 worth of Immunogen stock and bought 303,125 units worth $974,603 . The most active insiders traders include Biochem Incshire Pharmaceut..., Capital, L.P.Morton Holding..., and Mark J Enyedy. On average, Immunogen executives and independent directors trade stock every 34 days with the average trade being worth of $2,554,057. The most recent stock trade was executed by Stacy Ann Coen on 2 February 2024, trading 14,350 units of IMGN stock currently worth $448,294.
immunogen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate (adc) technology. the company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. leading healthcare companies have licensed rights to use immunogen's technology to develop novel anticancer therapies, and roche's marketed product, kadcyla, utilizes immunogen's adc technology. more information about the company can be found at www.immunogen.com.
Immunogen executives and other stock owners filed with the SEC include: